OHDSI’s mission is to improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care. As a community we envision a world in which observational research produces a comprehensive understanding of health and disease. OHDSI promotes a collaborative approach to research and has rapidly grown into a vibrant international community. Everyone is welcome to actively participate in OHDSI, whether as a patient, a health professional, a researcher, or someone who simply believes in our cause.
The 5th annual OHDSI symposium will promote this vision and provide OHDSI collaborators an opportunity to share our accomplishments with the broader healthcare community. The day will include a collaborator showcase involving a poster session to highlight OHDSI’s research achievements and interactive demonstrations of OHDSI’s open-source software tools that will revolutionize how medical evidence is generated.
The 2019 OHDSI symposium will take place Sept. 15-17 at the Bethesda North Marriott Hotel & Conference Center.
• The featured event is the symposium, which takes place Monday, Sept. 16. The full Monday agenda is available here, and the highlights include:
- Opening session by George Hripcsak, MD, MS and Harlan Krumholz, MD
- Plenary session on real-world evidence for regulatory decision-making, featuring three topics:
- Building confidence in real-world data: Data quality reporting (Clair Blacketer, MPH, PMP and Andrew Williams)
- Establishing scientific best practices for real-world analysis: The Book Of OHDSI (Martijn Schuemie, PhD and David Madigan, PhD)
- Proving reliable real-world evidence: Replicating RCTs using LEGEND (Patrick Ryan, PhD and George Hripcsak, MD, MS)
- A stakeholder panel, including representatives from the FDA, EMA, Saudi FDA, and Yale, will follow these talks
- An afternoon session highlighting three cases of OHDSI evidence in action:
- The EHDEN/Oxford Study-A-Thon explored knee arthroplasty (Peter Rijnbeek, PhD and Dani Prieto-Alhambra, MD, PhD)
- The Center for Surgical Sciences personalized surgery for colorectal cancer (Ismail Gôgenur, MD, DMSc and Gregory Klebanov, MS)
- The Women of OHDSI predicting breast cancer to improve screening (Maura Beaton, MS and the Women of OHDSI team)
- The OHDSI collaborator showcase, featuring poster presentations, lightning talks and software demonstrations from community contributions around the world
- While the symposium is free, a contribution is requested to attend the tutorials. You will need to register for the tutorials, which take place from 9 am to 5 pm both days (you can do one per day). Registration/contribution information is available here.
- Please note that registration for the tutorials is separate from registration for the symposium!
- Noémie Elhadad, PhD, Associate Professor of Biomedical Informatics at Columbia University Medical Center
- Violanda Grigorescu, MD, MSPH, Chief, Partnerships and Evaluation Branch in the Center for Surveillance, Epidemiology and Laboratory Services at the Centers for Disease Control and Prevention
- Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration
- Joanne Waldstreicher, MD, Chief Medical Officer at Johnson & Johnson
To help us plan for the Women in Real-World Analytics Leadership Forum, please register here.
Who Should Attend The 2019 U.S. OHDSI Symposium?
Stakeholders from the following organizations who would benefit from the presentations and discussions during and following this event, include but are not limited to:
- FDA, CMS, CDC, NIH, AHRQ, HHS, PCORI, DoD
- AMIA, Technology and Software developers
- Academia, Centers of Excellence
- Groups involved in the discovery of new pathways for treatment of cancer and other diseases
- Pharmaceutical and Device Industry
- Health-care start-ups, Healthcare payers and providers
- Clinicians, Patients, and Disease-focused Patient Advocates and Foundations
- Data standardization organizations
- People most interested in addressing these issues, because they are the most directly affected by the problems.
- Senior management interested in breaking the cycle